Champions of Care: Turnkey Solutions and How to Go Beyond Selling a Product

 

 

Matt Weismiller, CEO of Champion Chair, joined host Daniel Litwin on the first episode of Champions of Care to discuss the unique relationships that develop in the B2B side of healthcare, and what the ROI is of elevating your partnerships and your customer service in the industry.

Weismiller’s company is an industry leader in medical seating solutions, and Weismiller explained what his company does that goes beyond creating a necessary product.

“Being an expert supplier, or expert provider, is something you earn over time,” Weismiller said. “It’s important to lead in a consultative manner when you engage with a client. You can take a client through the capabilities your company has to offer that go beyond the capital product that you offer.”

How does a company shift its behavior from one where product sales are the most crucial goal for the company to one where long-term customer relationships and sales are most valued? Weismiller said it’s about earning the trust of the customer and building relationships that last a long time, not a one-time sale.

Weismiller’s used this approach throughout his career, and it’s the same solution-based, customer-focused model he brings to the culture at Champion Chair.

“I believe most companies are at their best form when they’re not just producing products as a commodity, but when they provide the product with services and capabilities that make it turnkey for the customer,” he said.

In an environment such as a healthcare setting, keeping up with technology can be a challenge. Healthcare services rely on the expertise of providers to keep up with the latest product solutions and bring those solutions to their customers. Weismiller said the journey to becoming a solutions-based product company doesn’t happen overnight, but is a trip that is worth taking.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More